Ketu Medicine was founded in August 2016 by Dr. Sun Zhijian, a former senior researcher of BeiGene, Mr. Kang Ping, a former co-founder of ACROBiosystems, and Professor Xie Dong, a professor and chief scientist at the Institute of Nutrition at the Chinese Academy of Sciences. The company is a pioneering domestic company focusing on the research, development, and commercial application of organoid technology in the Biopharma, Biotechnology, and Health Care industries. The core team members have extensive experience from well-known pharmaceutical companies, hospitals, scientific research institutions, and CROs such as Novartis, BeiGene, GE Healthcare, the Chinese Academy of Sciences, and 301 Hospital. Ketu Medicine received its Series B investment on 04 August 2022 from FOF Capital, a key milestone indicating growing investor confidence in the company's vision and potential. This investment will likely fuel the company's continued research and development efforts, as well as its commercialization activities. With its strong founding team and strategic investor backing, Ketu Medicine is well-positioned to make significant contributions to the field of organoid technology and impact the future of healthcare.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | Unknown | 1 | FOF Capital | 04 Aug 2022 |
| Venture Round | Unknown | 1 |
|
01 Jan 2016 |
No recent news or press coverage available for Ketu Medicine.
We care about your data, and we'd love to use cookies make your experience better.